Health technology assessment and reimbursement of pharmaceuticals in Italy
The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-li...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2019-07-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/295 |
| _version_ | 1797878889639313408 |
|---|---|
| author | F. V. Gorkavenko V. V. Omelyanovskiy T. P. Bezdenezhnykh G. R. Khachatryan |
| author_facet | F. V. Gorkavenko V. V. Omelyanovskiy T. P. Bezdenezhnykh G. R. Khachatryan |
| author_sort | F. V. Gorkavenko |
| collection | DOAJ |
| description | The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-listing. Some regions have established their own HTA institutions to define the reimbursement policy for a specific region or organization. Because of that, the entire HTA system in Italy can be characterized by low inter-regional coherence and insufficient coordination. As a result, the access to medical services is not unified at the regional level; in addition, it is difficult to collect and analyze the data required for providing value-based healthcare. Although the cost-effectiveness of specific health technologies is taken into consideration for decision-making, in practice, the main focus rests on the budget impact and cost control. Along with that, the AIFA holds the leading positions in Europe in using such innovative approaches as the patient access schemes, early HTA and horizon scanning. |
| first_indexed | 2024-04-10T02:40:12Z |
| format | Article |
| id | doaj.art-94b9f5e1aafc40d7b75e8f6f6b5bba69 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:40:12Z |
| publishDate | 2019-07-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-94b9f5e1aafc40d7b75e8f6f6b5bba692023-03-13T07:48:16ZrusIRBIS LLCФармакоэкономика2070-49092070-49332019-07-0112215616410.17749/2070-4909.2019.12.2.156-164265Health technology assessment and reimbursement of pharmaceuticals in ItalyF. V. Gorkavenko0V. V. Omelyanovskiy1T. P. Bezdenezhnykh2G. R. Khachatryan3Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian FederationResearch Institute of Finance, Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public AdministrationCenter for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Research Institute of Finance, Ministry of Finance of the Russian FederationCenter for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Research Institute of Finance, Ministry of Finance of the Russian FederationThe Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-listing. Some regions have established their own HTA institutions to define the reimbursement policy for a specific region or organization. Because of that, the entire HTA system in Italy can be characterized by low inter-regional coherence and insufficient coordination. As a result, the access to medical services is not unified at the regional level; in addition, it is difficult to collect and analyze the data required for providing value-based healthcare. Although the cost-effectiveness of specific health technologies is taken into consideration for decision-making, in practice, the main focus rests on the budget impact and cost control. Along with that, the AIFA holds the leading positions in Europe in using such innovative approaches as the patient access schemes, early HTA and horizon scanning.https://www.pharmacoeconomics.ru/jour/article/view/295health technology assessmentdrug provisiongovernmental pharmaceuticals reimbursementitaly |
| spellingShingle | F. V. Gorkavenko V. V. Omelyanovskiy T. P. Bezdenezhnykh G. R. Khachatryan Health technology assessment and reimbursement of pharmaceuticals in Italy Фармакоэкономика health technology assessment drug provision governmental pharmaceuticals reimbursement italy |
| title | Health technology assessment and reimbursement of pharmaceuticals in Italy |
| title_full | Health technology assessment and reimbursement of pharmaceuticals in Italy |
| title_fullStr | Health technology assessment and reimbursement of pharmaceuticals in Italy |
| title_full_unstemmed | Health technology assessment and reimbursement of pharmaceuticals in Italy |
| title_short | Health technology assessment and reimbursement of pharmaceuticals in Italy |
| title_sort | health technology assessment and reimbursement of pharmaceuticals in italy |
| topic | health technology assessment drug provision governmental pharmaceuticals reimbursement italy |
| url | https://www.pharmacoeconomics.ru/jour/article/view/295 |
| work_keys_str_mv | AT fvgorkavenko healthtechnologyassessmentandreimbursementofpharmaceuticalsinitaly AT vvomelyanovskiy healthtechnologyassessmentandreimbursementofpharmaceuticalsinitaly AT tpbezdenezhnykh healthtechnologyassessmentandreimbursementofpharmaceuticalsinitaly AT grkhachatryan healthtechnologyassessmentandreimbursementofpharmaceuticalsinitaly |